Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary vascular disease that is difficult to distinguish clinically from pulmonary arterial hypertension (PAH). Multiple genes have been implicated in disease pathogenesis in PAH and PVOD and the diseases are thought to be genetically distinct. In this report we present a case of first-degree relatives with pathological evidence of PVOD and PAH. The index patient was diagnosed with PAH at age 42, was treated with escalating pulmonary vasodilator therapy, but eventually succumbed to her disease. On autopsy, her pathology was consistent with PAH. Her son was diagnosed with PAH at age 16, did well on pulmonary vasodilator therapy for over 10 years, but ultimately developed refractory right ventricular failure and received a heart and lung transplantation. Pathology of his explanted lung was consistent with PVOD, and genetic testing was negative for recognized variants that cause PAH or PVOD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588353PMC
http://dx.doi.org/10.1002/rcr2.70064DOI Listing

Publication Analysis

Top Keywords

pah
8
pvod pah
8
pulmonary vascular
8
pah pvod
8
diagnosed pah
8
pah age
8
pulmonary vasodilator
8
vasodilator therapy
8
pvod
6
pulmonary
6

Similar Publications

Pleural effusions (PLEF) in pulmonary arterial hypertension (PAH), particularly in patients with isolated right heart failure, are associated with poor prognosis and increased mortality. This study investigates changes in alveolar fluid clearance (AFC) transporter expression in relation to lung fluid accumulation and PLEF formation during PAH progression, as well as the effects of terbutaline (TER) and riociguat (RIO) treatment. Using a monocrotaline (MCT)-induced pulmonary hypertension (PH) rat model, we performed a detailed molecular analysis of AFC transporter expression at different disease stages, both before and after PH development.

View Article and Find Full Text PDF

Background: Disulfidptosis, a novel cellular death manner, has yet to be fully explored within the context of pulmonary arterial hypertension (PAH). This study aims to identify genes implicated in PAH that are involved in disulfidptosis.

Method: Based on data from the GEO database, this study employed co-expression analysis, Weighted Gene Co-Expression Network Analysis (WGCNA), hub gene identification, and Gene Set Enrichment Analysis (GSEA) to uncover genes associated with PAH and disulfidptosis.

View Article and Find Full Text PDF

Right ventricular (RV) failure is the primary cause of death among patients with pulmonary arterial hypertension (PAH). Patients with congenital heart disease-associated PAH (CHD-PAH) demonstrate improved outcomes compared to patients with other forms of PAH, which is related to the maintenance of an adaptively hypertrophied RV. In an ovine model of CHD-PAH, we aimed to elucidate the cellular, microvascular, and transcriptional adaptations to congenital pressure overload that support RV function.

View Article and Find Full Text PDF

Portopulmonary hypertension (POPH), a subtype of pulmonary arterial hypertension (PAH), develops with portal hypertension and may persist after liver transplantation. While there have been successes using balloon-occluded retrograde transvenous obliteration (BRTO) for POPH, no reports exist on long-term follow-up. A 60-year-old man with hepatitis C cirrhosis developed POPH.

View Article and Find Full Text PDF

Background: BMPR2 mutations cause heritable pulmonary arterial hypertension (PAH) and may also influence epithelial carcinogenesis.

Case Summary: We report 3 women with BMPR2-related PAH who developed early onset epithelial cancers: 2 breast cancers (34 and 54 years of age) and 1 colorectal cancer (47 years of age). All were on advanced PAH therapy at diagnosis.

View Article and Find Full Text PDF